Parkwood LLC Reduces Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Parkwood LLC reduced its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 85.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,347 shares of the biopharmaceutical company’s stock after selling 141,067 shares during the period. Parkwood LLC’s holdings in TG Therapeutics were worth $416,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of TGTX. Pingora Partners LLC purchased a new stake in TG Therapeutics in the fourth quarter worth about $27,000. PNC Financial Services Group Inc. lifted its holdings in TG Therapeutics by 131.7% in the third quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,014 shares during the period. Anchor Investment Management LLC purchased a new stake in TG Therapeutics in the fourth quarter worth about $80,000. Sherbrooke Park Advisers LLC purchased a new stake in TG Therapeutics in the third quarter worth about $104,000. Finally, Clark Financial Services Group Inc. BD lifted its holdings in TG Therapeutics by 15.1% in the third quarter. Clark Financial Services Group Inc. BD now owns 14,195 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 1,860 shares during the period. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Stock Down 0.3 %

Shares of TGTX traded down $0.05 on Thursday, hitting $16.76. 1,368,673 shares of the stock traded hands, compared to its average volume of 3,915,792. The company has a market capitalization of $2.59 billion, a PE ratio of 72.87 and a beta of 2.30. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.84 and a current ratio of 3.62. The business has a 50 day simple moving average of $15.72 and a 200 day simple moving average of $15.82. TG Therapeutics, Inc. has a one year low of $6.46 and a one year high of $27.80.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). TG Therapeutics had a return on equity of 31.34% and a net margin of 14.24%. The company had revenue of $63.47 million during the quarter, compared to the consensus estimate of $54.60 million. During the same period last year, the firm posted ($0.28) EPS. The company’s revenue for the quarter was up 713.5% on a year-over-year basis. As a group, equities analysts forecast that TG Therapeutics, Inc. will post -0.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on TGTX shares. LADENBURG THALM/SH SH lifted their target price on shares of TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. HC Wainwright lifted their target price on shares of TG Therapeutics from $45.00 to $49.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. JPMorgan Chase & Co. reiterated an “overweight” rating and set a $25.00 target price on shares of TG Therapeutics in a report on Thursday, April 18th. StockNews.com lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 24th. Finally, The Goldman Sachs Group lifted their target price on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Thursday, February 29th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.83.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.